CureTech, Medivation deal

Medivation received exclusive, worldwide rights to CureTech’s pidilizumab ( CT-011), a humanized anti- programmed cell death 1 ( PDCD1; PD-1; CD279) mAb. CureTech will receive $5 million up front and is eligible for development and regulatory milestones of up to $85 million, sales milestone payments of up to $245 million and tiered royalties of 4-11%. ...